Intracardiac grafts comprised of genetically modified skeletal myoblasts were assessed for their ability to effect longterm delivery of recombinant transforming growth factorj3 (TGF-8) to the heart. C2C12 myoblasts were stably transfected with a construct comprised of an inducible metallothionein promoter fused to a modified TGF-131 cDNA. When cultured in medium supplemented with zinc sulfate, cells carrying this transgene constitutively secrete active TGF-fi1. These genetically modified myoblasts were used to produce intracardiac grafts in syngeneic C3Heb/FeJ hosts. Viable grafts were observed as long as three months after implantation, and immunohistological analyses of mice maintained on water supplemented with zinc sulfate revealed the presence of grafted cells which stably expressed TGF-fi1. Regions of apparent neovascularization, as evidenced by tritiated thymidine incorporation into vascular endothelial cells, were observed in the myocardium which bordered grafts expressing TGF-fi1. The extent of vascular endothelial cell DNA synthesis could be modulated by altering dietary zinc. Similar effects on the vascular endothelial cells were not seen in mice with grafts comprised of nontransfected cells. This study indicates that genetically modified skeletal myoblast grafts can be used to effect the local, long-term delivery of recombinant molecules to the heart. (J. Clin. Invest. 1995. 95:114-121.)
Introduction
Cellular grafting has emerged as an accepted approach for the delivery of therapeutic agents to patients. For example, intracerebral grafting of fetal adrenal tissue in Parkinson's patients has gained support as an effective means to supplement dopamine levels (for review see reference 1). More recently, the use of genetically modified cells for the delivery of recombinant molecules has emerged as a powerful approach for ex vivo gene therapy. Several experimental animal models which use a variety of cell types to deliver recombinant molecules to the brain, thymus, and hematopoietic system have recently appeared (for review see references [2] [3] [4] [5] . Using an analogous approach in humans, autologous transplantation of bone marrow cells transfected with an adenosine deaminase expression construct has been used in an attempt to treat patients lacking this enzyme (6) . More recently, ex vivo gene therapy with autologous hepatocytes has been successfully used to target expression of recombinant LDL receptor in a patient with familial hypercholesterolaemia, resulting in an improved plasma LDL/HDL ratio (7) .
Skeletal myoblasts possess several attributes which have proven to be beneficial for grafting experiments, particularly into muscle beds. For example, primary myoblasts can be isolated from numerous species including humans; the use of autologous grafts comprised of amplified primary myoblasts could eliminate immune rejection. In addition, skeletal myoblasts are genetically tractable, thereby allowing the introduction of recombinant genes in vitro. When engrafted into the skeletal muscle beds of mdx mice, primary myoblasts from normal mice differentiated and fused with diseased host myotubes (8) . The resulting heterokaryons expressed dystrophin. Heterokaryon formation in these models was dependent upon the ability of myoblasts to traverse the basal lamina of pre-existing myotubes (9) . These later observations suggested that myoblast grafting might constitute a potential therapeutic intervention for Duchenne's patients. Although initial efforts to treat patients with this approach appear to have attained some degree of success in that a limited number of dystrophin-positive cells could be detected in muscle biopsies from engrafted patients (10), the procedure is not without controversy (11) .
Genetically modified skeletal myoblast grafts have been successfully used to deliver recombinant proteins in experimental animals. Stably transfected myoblasts injected intramuscularly into the limbs of mice effectively elevated plasma growth hormone levels for up to 80 d after grafting (12, 13) . In more recent studies primary myoblasts transfected with a tyrosine hydroxylase expression construct have been engrafted into the brain of rats with unilateral striatal denervation (14) . Dopamine and L-DOPA secretion from the grafted myocytes correlated inversely with rotational behavior in this surgical model of Par- kinson's disease.
The use of intracardiac grafting to effect long-term delivery of recombinant proteins could induce a beneficial response in the myocardium. For (17) . Moreover, no deleteri-ous effects on host cardiac function were observed. Unfortunately, because AT-i cardiomyocytes are transformed, their utility for producing long-term intracardiac grafts is somewhat limited. Subsequent studies utilized C2C12 myoblasts to form intracardiac grafts (18) . Grafted myoblasts differentiated and fused to form nascent myotubes within the host myocardium. Furthermore, grafted C2C12 myoblasts withdrew from the cell cycle upon myodifferentiation; consequently, proliferation of graft myocytes was not an issue with this model.
The present study examined the capacity of genetically engineered myoblasts to effect long term delivery of recombinant protein to the heart. C2C12 myoblasts were stably transfected with a fusion gene comprised of the metallothionein promoter and a TGF-,31 cDNA. TGF-fi I's activity as an angiogenic factor in vivo is well characterized (19) . Moreover, it has recently been suggested that TGF-f31 exhibits cardioprotective properties (20) . Recombinant TGF-,f1 expression was readily detected in grafts generated with modified C2C12 myoblasts, but not in control grafts. Furthermore, evidence for enhanced neovascularization was observed in the myocardium bordering grafts expressing TGF-,3 1 . The implication of these results with respect to the potential long-term delivery of recombinant proteins to the heart is discussed.
Methods
C2C12 cell culture and transfection. C2C12 myoblasts (American Type Culture Collection, Rockville, MD) were maintained in the undifferentiated state by culturing at low density in high glucose DME supplemented with 20% fetal bovine serum, 1% chicken embryo extract, 100 U/ml penicillin, and 100 /ig/ml streptomycin. For some studies, myogenic differentiation was induced by culturing in DME supplemented with 2% horse serum and antibiotics.
Transfections utilized pPK9a, a TGF-,61 expression vector under the control of the metallothionein promoter, kindly provided by P. Kondaiah (21) . pPK9a was stably cotransfected with the neomycin resistance gene into C2C12 cells by the calcium phosphate precipitation method. Neomycin-resistant colonies were screened for expression of the recombinant TGF-31 transcripts in the presence of 100 uM zinc sulfate.
Myocardial grafting protocol. Immediately before injection, transfected and control myoblasts were harvested with trypsin, washed three times with serum-free DME, and directly injected into the ventricular myocardium of adult syngeneic C3Heb/FeJ mice (Jackson Laboratories, Bar Harbor MA) under open heart surgery as described (17, 18 ). 4-10 x 10' cells were injected in a volume of 2-3 MI using a plastic syringe fitted with a 30-gauge needle. 1 mo after surgery, graft bearing animals were given heavy metal (25 mM zinc sulfate in drinking water), and treatment was continued until the termination of the experiment (7-50 d) .
Northern blot analysis. Cells were plated onto 150-mm tissue plates.
At 70-80% confluence, TGF-,l6 secretion was induced by 100 MM zinc sulfate. After 24 h of incubation, total RNA was isolated as described (22) . 10 pg of each sample of total RNA was run on a 1.0% agarose, 1.1 M formaldehyde gel, and blotted onto a Duralon-UVTM membrane (Stratagene, La Jolla, CA). Prehybridization, hybridization, and washing of the filters were as described (23) . RNA blots were hybridized with probes corresponding to the rat TGF-,51 cDNA (24) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)' cDNA (25) .
Preparation of conditioned medium and CCL64 mink lung growth inhibition assay. Cell lines were cultured in 100-mm tissue culture plates in high glucose DME supplemented with 20% fetal bovine serum. At 1. Abbreviations used in this paper: FGF, fibroblast growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase, H and E, hematoxylin and eosin; VEGF, vascular endothelial growth factor. 70-80% confluency, cells were washed once with serum-free medium and then cultured in DME supplemented with 100 tg/ml BSA fraction V for 24 h with or without either 50 or 100 ILM zinc sulfate. Conditioned media were centrifuged, and then 1 pg/ml aprotinin, 2 pg/ml leupeptin, and 120 ,g/ml PMSF were added. The amount of TGF-,B being secreted into the medium was determined by the CCL64 growth inhibition assay as described (26 Ci/mM; Amersham, Arlington Heights, IL) and sacrificed 14 h later. The heart was removed and processed for paraffin embedding as described above. For autoradiography, deparaffinized sections were stained with H and E, and coated with a thin layer of photographic emulsion (Ilford L.4; Polysciences Inc., Warrington, PA) diluted 1:1 with distilled water. Sections were exposed for 5-7 d at 4C, and developed in Kodak D-19 (Eastman Kodak Co., Rochester, NY) at 20C for 4 min, washed with distilled water for 1 min, fixed in 30% sodium thiosulfate for 10 min, and washed in distilled water. Immunohistologic analyses with anti-von Willebrand Factor (vWf) antibody (Dako Corp., Carpinteria, CA) was used to localize vascular endothelial cells according to the supplier's recommendations. Monoclonal antibody against the common leukocyte antigen (CD25; antibody M1/9.3HL; Boehringer Mannheim, Indianapolis, IN) was used to monitor immune rejection of the targeted recombinant TGF-# 1. This antibody recognizes all lymphoid and hematopoietic cells, including B and T lymphocytes, monocytes, and granulocytes. After treatment with primary antibody, sections were incubated with horseradish peroxidase-conjugated rabbit anti-rat antisera (Boehringer Mannheim), and visualized by the ABC kit according to the manufacturer's protocol (Vector Laboratories, Inc.).
Assessment of myocardial vascular endothelial cell DNA synthesis. To quantitate vascular endothelial DNA synthesis, samples were monitored via a Sony CCD television camera mounted on a Leitz Labrolux microscope, and images were displayed on a video monitor. The number of synthetic vascular endothelial cells, as evidenced by tritiated thymidine incorporation, which resided within 500 [.m of the graft/myocardium border were counted. The cumulative length of the graft/myocardium border for each experimental series was also determined. Results are expressed as the ratio of the total number of synthetic vascular endothelial cells divided by the cumulative length (arbitrary units) of graft/myocardium border. Data is presented as means ± standard error. A nested group t test was used for statistical analyses.
Results
A fusion gene comprised of the metallothionein promoter driving a modified TGF-f31 cDNA was described previously (21) .
Transcriptional activity of the metallothionein promoter can be regulated by modulating the heavy metal content of cell culture medium. The TGF-,il cDNA carried site-directed mutations which resulted in the conversion of cysteine223 and cysteine225 to serines. This modification (28) results in the elaboration of a TGF-,61 molecule in which the portion of the prepro domain which is processed to the latency associated protein (LAP) is unable to form dimers, and consequently cannot confer latency Graft-induced Myocardial Neovascularization on mature TGF-P. Cells expressing the modified cDNA constitutively secreted active TGF-/31 (21 (Fig. 1 A) . Addition of heavy metal to the culture medium resulted in a marked increase of recombinant TGF-f31 transcripts in C2(280) myoblasts and myotubes. As indicated above, modified TGF-,lf expressed by C2(280) cells should have constitutive biological activity. To directly test this, conditioned medium from C2(280) myoblasts and myotubes was examined by the CCL-64 growth inhibition assay (26) . When induced, C2(280) cells secreted TGF-f3 at a rate of 31 ng/106 cells/24 h, 9.6-fold more than in the uninduced state ( Fig. 1 B) . Furthermore, after zinc sulfate treatment, a very high proportion of the TGF-,f (49%) was active in neutral conditioned medium and did not require acid activation.
C2(280) myoblasts were used to produce intracardiac grafts in syngeneic C3Heb/FeJ mice. The presence of grafts was readily detected in H and E stained sections (Fig. 2 A) . 100% of the animals receiving intracardiac injections of C2(280) cells went on to develop grafts. Interestingly, H and E analysis suggested that the C2(280) grafts were somewhat less differentiated as compared with those produced with unmodified C2C12 cells (compare Fig. 2 , A and C; see also reference 18, Discussion). The differentiated state of the engrafted C2(280) cells was further explored by immunohistologic analysis with a monoclonal antibody specific for skeletal myosin heavy chain; nascent myotubes appeared somewhat disorganized in C2(280) grafts as compared with control C2C12 grafts (data not shown).
Graft transgene expression was assessed by immunohistology with an anti-TGF-fl1 antibody (27) . TGF-f31 expression was readily detected in C2(280) grafts when the host animal was maintained on zinc supplemented water (Fig. 2 B) . Furthermore, removal of zinc resulted in a marked decrease in graft TGF-,61 expression (data not shown). As a negative control, TGF-PI1 expression was assessed in grafts produced by untransfected C2C12 myoblasts (Fig. 2 D) . As expected, TGF-fil expression was virtually undetectable in the C2C12 grafts (Fig. 2 D) . Although surface electrocardiograms of either C2C12 or C2(280) engrafted mice were normal, the relatively high heart rate in mice might render these animals resistant to experimentally induced arrhythmia. As such, potential arrhythmogenic effects of chronic TGF-f61 delivery might not be detected in this model. grafts. This tendency is documented by the selected photomicrographs in Fig. 2 , E and F, which depict the extremes of capillary density observed in the myocardium bordering C2(280) and C2C12 grafts, respectively. The vWf immunohistological results suggested the possibility of enhanced myocardial angiogenesis in the TGF-/31 expressing animals. However, given that the heart is highly vascularized to begin with, it was difficult to objectively ascertain the extent of neovascularization using an assay measuring blood vessel density. An assay able to monitor blood vessel growth would provide a more useful assessment of the in vivo effects of targeted TGF-f31 expression. Since Fig. 2 shows a representative section of the heart from one of the C2(280) engrafted animals. The section was stained with an anti-vWf antibody and then processed for autoradiography. Immunofluorescence photomicroscopy clearly revealed the presence of a large blood vessel in the myocardium bordering the TGF-L31 expressing graft (Fig. 2 G) . Bright field analysis of the same field indicates that six of the endothelial cells in this blood vessel were actively synthesizing DNA, as evidenced by the presence of nuclear-localized silver grains in the autoradiograph (Fig. 2 H) . Thymidine incorporation was also evident in the underlying media; however, given the ease with which vascular endothelial cells can be identified in H and E stained sections, assessment of DNA synthesis in these cells was used for quantitation purposes. As indicated Table I. different from C2C12 controls.
above our assumption is that the presence of DNA vascular endothelial cells equates to cell division quently blood vessel growth.
To determine if the observed vascular endotheli synthesis was due to the expression of recombin, synthetic activity was compared between hearts c ther C2C12 or C2(280) grafts (Fig. 3, Table I ). Va thelial cell DNA synthesis was monitored after eii wk of zinc induction. To Fig. 3 represent only the relative levels of DNA synthesis between the two graft types. In terms of°a bsolute numbers, only a small fraction of the total vascular endothelial cells were synthetic, an observation which is underscored by the fact that on average only 2.9 synthetic cells were rdial vascular observed per microscopic section (35 synthetic cells/12 wholernthetic vascuheart sections, see Table I) . mpared for
The level of myocardial vascular endothelial cell DNA syng, zinc sulfate thesis was also assessed at 6.5 wk after zinc induction (Fig. 3, After tritiated Table I ). In an attempt to further support the notion that the observed in vivo effects were due to recombinant TGF-,l3l expression, we ascertained whether a dose-response relationship between transgene activity and myocardial vascular endothelial synthesis in cell DNA synthesis could be detected. As indicated above, the and conse-MT-C2(280) transgene is inducible in vitro (Fig. 1) , and the MT promoter is also known to be inducible in vivo (29) . We ial cell DNA therefore compared the extent of myocardial vascular endotheant TGF-,B1, lial cell DNA synthesis in mice with C2(280) grafts maintained ontaining eion either high or low dietary zinc for 6.5 wk (that is, animals scular endowith or without dietary zinc supplement; see Fig. 3 , Table I ). ther 1 endothelial cell DNA synthesis was observed for the C2(280) engrafted animals maintained on low dietary zinc, the differences did not reach statistical significance with the limited number of animals employed in this.study. The TGF-/31 cDNA used in this study was isolated from a porcine cDNA library (21) . Given that this protein is foreign, experiments were initiated to determine if an immunologic response could be detected in C2(280) engrafted hearts. H and E analyses failed to detect obvious monocyte infiltration in TGF-/31 expressing C2(280) grafts (Fig. 4 A) . This observation was confirmed by immunohistology with antibody specific for the common leukocyte antigen CD25. This antibody recognizes all lymphoid and hematopoietic cells, including B and T lymphocytes, monocytes and granulocytes. No immunoreactivity was observed in the TGF-f31 expressing C2(280) grafts from animals maintained on high dietary zinc for a period of 6.5 wk (Fig. 4  B) . Strong anti-leukocyte signal was observed in a remote blood vessel, providing a positive control for the experiment. The absence of a detectable immune response further supports the contention that the observed in vivo effects in the C2(280) engrafted hearts is due to the biological activity of TGF-,B1, as opposed to an auto-immune phenomenon. Finally, it should be noted that thymidine incorporation also revealed that low levels of C2(280) myocyte DNA synthesis could be detected in animals maintained on both low and high dietary zinc. This observation is consistent with the known inhibitory effect of TGF-/B1 on myodifferentiation (30, 31) , and most likely accounts for the somewhat undifferentiated appearance of the C2(280) grafts mentioned above. Similar levels of DNA synthesis were not apparent in the control C2C12 grafts which do not express recombinant TGF-fi1, in agreement with our previous results (18 Although this study indicates that cellular grafting approaches can be used for the long-term delivery of recombinant molecules to the heart, the model is not without flaws. Specifically, the subpopulation of C2(280) myoblasts failing to undergo terminal differentiation, as evidenced by tritiated thymidine incorporation, deserves mention. It is well known that exogenous growth factors, including both TGF-,31 and a-and /3-fibroblast growth factors (FGFs), can interfere with myogenic differentiation in culture (30) (31) (32) . A recent study has shown that activated protein kinase C (PKC) mimics the effects of TGF-f31 and FGFs on myodifferentiation (33 reference 34) . Unlike other putative angiogenic factors, the mitogenic activities of VEGF appear to be endothelial cell specific (35) . It has been recently shown that VEGF is a high affinity ligand for a receptor tyrosine kinase known as flk-I (for fetal liver kinase-l, see reference 36). In situ analyses show correlations in the spatial and temporal patterns of VEGF and flk-l expression in developing mouse embryos, lending further support to the notion that VEGF is a major regulator of angiogenesis. Given these considerations, long-term expression of VEGF in intracardiac grafts might induce neovascularization in the adult myocardium without the deleterious effects on myodifferentiation observed with TGF-,61 in the present study.
Several other approaches to effect long-term delivery of recombinant molecules to the myocardium have recently been described. One approach is based on the observation that DNA injected directly into skeletal muscle beds is expressed in vivo (37) . Subsequent studies from several groups have shown that this approach is also viable in the heart (38, 39) . Although the injected DNA exhibited relatively low transfection efficiencies and a highly variable half-life in the initial studies, reporter gene expression as long as 19 mo after injection into skeletal muscle has recently been reported (40) . The injected DNA remained episomal and did not replicate in this study. A second approach being explored for myocardial gene therapy relies on the use of recombinant adenovirus. Cardiomyocytes can be efficiently transfected in vitro with recombinant adenoviruses (41) . Moreover, long-term reporter gene expression was observed in both skeletal and cardiac muscle following intravenous delivery of recombinant virus in mice (42) . In other studies, adenovirus was readily delivered to both the coronary vasculature and to heart muscle via cardiac catheterization in rabbits (43) . These approaches hold great promise for the delivery of gene products to the myocardium, although problems are currently encountered with both temporal limitations of transgene expression and "down-streaming" effects (i.e., viruses delivered to the myocardium can find their way to other organs via the blood stream). This latter problem might be solved by the use of cell type-specific promoters.
Myocardial (18) . Although unlikely, it remained a formal possibility that the intracardiac grafts observed in this previous study may have arisen as a consequence of C2C12 myoblast-mediated induction of myogenic differentiation in host cardiac fibroblasts. In contrast, the present study used genetically modified myoblasts. The 
